CFLT Form 4: CFO Rohan Sells 5,000 Shares via 10b5-1 Plan
Rhea-AI Filing Summary
Confluent, Inc. (CFLT) Chief Financial Officer Sivaram Rohan reported a sale of 5,000 shares of Class A common stock on 09/08/2025 at a price of $20.00 per share. The sale was made pursuant to a 10b5-1 trading plan dated September 12, 2024. After the reported transaction, the reporting person beneficially owned 631,596 shares of Class A common stock. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Positive
- Sale executed under a 10b5-1 trading plan, indicating the transaction was prearranged and reduces concerns about opportunistic insider trading
- High retained ownership: the reporting person still beneficially owns 631,596 shares, showing continued significant stake
Negative
- None.
Insights
TL;DR: Routine insider sale under a prearranged plan; small transaction relative to total holdings, limited immediate market impact.
The 5,000-share sale executed at $20 per share was processed under a 10b5-1 plan, indicating it was pre-specified and not a discretionary trade. With 631,596 shares remaining beneficially owned, the transaction represents a small percentage of the reporting person’s stake and is unlikely to signal a change in insider conviction. For investors, this Form 4 documents compliance and transparency rather than new information about company fundamentals.
TL;DR: Disclosure aligns with governance best practices; use of 10b5-1 plan reduces regulatory and insider-trading concerns.
The filing clearly states the trade was made pursuant to a 10b5-1 trading plan, which is consistent with governance practices to avoid accusations of opportunistic insider trading. The Form 4 includes the requisite detail: transaction date, number of shares sold, price, and post-transaction beneficial ownership. The signature by an attorney-in-fact completes the reporting requirement. No governance red flags are evident from this single disclosure.
FAQ
What transaction did Confluent (CFLT) insider Sivaram Rohan report on Form 4?
Was the sale by the Confluent CFO discretionary or prearranged?
How many Confluent shares does the reporting person own after the sale?
What price was reported for the shares sold by the Confluent insider?
Who signed the Form 4 for the Confluent insider filing?